From the publishers of JADPRO

Graft-vs.-Host Disease Resource Center

Advertisement

363 Phase I/II Clinical Trials of Donor-Derived Purified Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft Versus Host Disease

Last Updated: Monday, December 12, 2022

Phase 1/2 clinical trials demonstrate that infusing donor regulatory T cells for the treatment of steroid-refractory/dependent chronic GVHD produced meaningful responses that should be explored further in a larger phase 2 trial.

2022 ASH Annual Meeting
Advertisement
News & Literature Highlights
Advertisement
Advertisement